Biomarker Rule-in or Rule-out in Patients With Acute Diseases for Validation of Acute Kidney Injury in the Emergency Department (BRAVA): A Multicenter Study Evaluating Urinary TIMP-2/IGFBP7
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Urine tissue inhibitor of metalloproteinases-2/insulin-like growth factor-binding protein 7 (TIMP-2/IGFBP7) (NephroCheck, Ortho Clinical Diagnostics, Raritan, NJ, USA) is a US Food and Drug Administration-approved biomarker for risk assessment of acute kidney injury (AKI) in critically ill adult patients in intensive care units; however, its clinical impact in the emergency department (ED) remains unproven. We evaluated the utility of NephroCheck for predicting AKI development and short-term mortality in the ED. Methods: This was a prospective, observational, five-center international study. We consecutively enrolled ED patients admitted with ≥30% risk of AKI development (assessed by ED physician: ED score) or acute diseases. Serum creatinine was tested on ED arrival (T0), day 1, and day 2 (T48); urine for NephroCheck was collected at T0 and T48. We performed ROC curve and reclassification analyses. Results: Among the 529 patients enrolled (213 females; median age, 65 years), AKI developed in 59 (11.2%) patients. The T0 NephroCheck value was higher in the AKI group than in the non-AKI group (median 0.77 vs. 0.29 (ng/m)2/1,000, P=0.001), and better predicted AKI development than the ED score (area under the curve [AUC], 0.64 vs. 0.53; P=0.04). In reclassification analyses, adding NephroCheck to the ED score improved the prediction of AKI development (P<0.05). The T0 NephroCheck value predicted 30-day mortality (AUC, 0.68; P<0.001). Conclusions: NephroCheck can predict both AKI development and short-term mortality in at-risk ED patients. NephroCheck would be a useful biomarker for early ruling-in or ruling-out of AKI in the ED.
Abstract
Background: Urine tissue inhibitor of metalloproteinases-2/insulin-like growth factor-binding protein 7 (TIMP-2/IGFBP7) (NephroCheck, Ortho Clinical Diagnostics, Raritan, NJ, USA) is a US Food and Drug Administration-approved biomarker for risk assessment of acute kidney injury (AKI) in critically ill adult patients in intensive care units; however, its clinical impact in the emergency department (ED) remains unproven. We evaluated the utility of NephroCheck for predicting AKI development and short-term mortality in the ED. Methods: This was a prospective, observational, five-center international study. We consecutively enrolled ED patients admitted with ≥30% risk of AKI development (assessed by ED physician: ED score) or acute diseases. Serum creatinine was tested on ED arrival (T0), day 1, and day 2 (T48); urine for NephroCheck was collected at T0 and T48. We performed ROC curve and reclassification analyses. Results: Among the 529 patients enrolled (213 females; median age, 65 years), AKI developed in 59 (11.2%) patients. The T0 NephroCheck value was higher in the AKI group than in the non-AKI group (median 0.77 vs. 0.29 (ng/m)2/1,000, P=0.001), and better predicted AKI development than the ED score (area under the curve [AUC], 0.64 vs. 0.53; P=0.04). In reclassification analyses, adding NephroCheck to the ED score improved the prediction of AKI development (P<0.05). The T0 NephroCheck value predicted 30-day mortality (AUC, 0.68; P<0.001). Conclusions: NephroCheck can predict both AKI development and short-term mortality in at-risk ED patients. NephroCheck would be a useful biomarker for early ruling-in or ruling-out of AKI in the ED.
참고문헌 (34)
- Susantitaphong P, "World incidence of AKI : a meta-analysis", Clin J Am Soc Nephrol, 8, pp.1482~1493 (2013)
- Hoste EA, "Epidemiology of acute kidney injury in critically ill patients : the multinational AKI-EPI study", Intensive Care Med, 41, pp.1411~1423 (2015)
- Group KDIGOAKIW, "KDIGO clinical practice guideline for acute kidney injury", Kidney Int, 2, pp.1~138 (2012)
- Meersch M, "Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers : the PrevAKI randomized controlled trial", Intensive Care Med, 43, pp.1551~1561 (2017)
- Cervellin G, "Neutrophil gelatinase-associated lipocalin(NGAL) : the clinician’s perspective", Clin Chem Lab Med, 50, pp.1489~1493 (2012)
- Mehta RL, "Acute Kidney Injury Network : report of an initiative to improve outcomes in acute kidney injury", Crit Care, 11, pp.R31~ (2007)
- Teixeira C, "Fluid balance and urine volume are independent predictors of mortality in acute kidney injury", Crit Care, 17, pp.R14~ (2013)
- Bellomo R, "Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group", Crit Care, 8, pp.R204~12 (2004)
- Thomas ME, "The definition of acute kidney injury and its use in practice", Kidney Int, 87, pp.62~73 (2015)
- Endre ZH, "Clearance and beyond : the complementary roles of GFR measurement and injury biomarkers in acute kidney injury(AKI)", Am J Physiol Renal Physiol, 301, pp.F697~F707 (2011)
- Kashani K, "Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury", Crit Care, 17, pp.R25~ (2013)
- Fan W, "Current understanding and future directions in the application of TIMP-2 and IGFBP7 in AKI clinical practice", Clin Chem Lab Med, 57, pp.567~576 (2019)
- Bihorac A, "Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication", Am J Respir Crit Care Med, 189, pp.932~939 (2014)
- "US Food and Drug Administration letter to Astute Medical" (2014)[URL]
- for acute kidney injury risk assessment, "Am J Kidney Dis", 2016, 19~28
- Ilaria G, "Clinical adoption of Nephrocheck in the early detection of acute kidney injury", Ann Clin Biochem, 58, pp.6~15 (2021)
- McCullough PA, "B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure : analysis from Breathing Not Properly(BNP)Multinational Study", Circulation, 106, pp.416~422 (2002)
- Di Somma S, "Additive value of blood neutrophil gelatinase-associated lipocalin to clinical judgement in acute kidney injury diagnosis and mortality prediction in patients hospitalized from the emergency department", Crit Care, 17, pp.R29~ (2013)
- Levey AS, "A new equation to estimate glomerular filtration rate", Ann Intern Med, 150, pp.604~612 (2009)
- Janssens ACJW, "Reflection on modern methods : revisiting the area under the ROC curve", Int J Epidemiol, pp.1397~1403 (2020)
- Pencina MJ, "Evaluating the added predictive ability of a new marker : from area under the ROC curve to reclassification and beyond", Stat Med, 27, pp.157~172 (2008)
- Kimmel M, "Association of renal stress", damage and filtration biomarkers with subsequent AKI during hospitalization among patients presenting to the emergency department, 2016, pp.11, 938~946
- for risk prediction of acute kidney injury in decompensated heart failure, "Clin Cardiol", 2017, 485~491
- -guided randomized controlled intervention trial to prevent acute kidney injury in the emergency department, "Nephrol Dial Transplant", 2019, 1902~1909
- Hoste EA, "Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome", J Am Soc Nephrol, 14, pp.1022~1030 (2003)
- Johnson ACM, "Mechanisms underlying increased TIMP2 and IGFBP7 urinary excretion in experimental AKI", J Am Soc Nephrol, 29, pp.2157~2167 (2018)
- Ronco C, "Subclinical AKI is still AKI", Crit Care, 16, pp.313~ (2012)
- McCullough PA, "Diagnosis of acute kidney injury using functional and injury biomarkers : workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference", Contrib Nephrol, 182, pp.13~29 (2013)
- Albert Christian, "Biomarker-Guided Risk Assessment for Acute Kidney Injury: Time for Clinical Implementation?", Annals of Laboratory Medicine, 41(1), pp.1~15 (2021), 대한진단검사의학회[DOI]
- Göcze I, "Biomarker-guided intervention to prevent acute kidney injury after major surgery : the prospective randomized BigpAK study", Ann Surg, 267, pp.1013~1020 (2018)
- Chawla LS, "Acute kidney disease and renal recovery : consensus report of the Acute Disease Quality Initiative(ADQI)16 Workgroup", Nat Rev Nephrol, 13, pp.241~257 (2017)
- Lin J, "False-positive rate of AKI using consensus creatinine-based criteria", Clin J Am Soc Nephrol, 10, pp.1723~1731 (2015)
- El-Khoury JM, "AACC Guidance Document on laboratory investigation of acute kidney injury", J Appl Lab Med, pp.jfab020~ (2021)[DOI]
- Yeh HC, "24-hour serum creatinine variation associates with short-and long-term all-cause mortality : a real-world insight into early detection of acute kidney injury", Sci Rep, 10, pp.6552~ (2020)